These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35804404)

  • 1. Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.
    Marchand A; Caille A; Gissot V; Giraudeau B; Lengelle C; Bourgoin H; Largeau B; Leducq S; Maruani A
    Trials; 2022 Jul; 23(1):557. PubMed ID: 35804404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
    Leducq S; Caille A; Barbarot S; Bénéton N; Bessis D; Boccara O; Bursztejn AC; Chiaverini C; Dompmartin A; Droitcourt C; Gissot V; Goga D; Guibaud L; Herbreteau D; Le Touze A; Léauté-Labrèze C; Lorette G; Mallet S; Martin L; Mazereeuw-Hautier J; Phan A; Plantin P; Quéré I; Vabres P; Bourgoin H; Giraudeau B; Maruani A;
    Trials; 2019 Dec; 20(1):739. PubMed ID: 31847908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
    Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
    Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
    Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
    JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Topical Sirolimus (Rapamycin) for the Treatment of Microcystic Lymphatic Malformations.
    Ivars M; Redondo P
    JAMA Dermatol; 2017 Jan; 153(1):103-105. PubMed ID: 27784048
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series.
    Le Sage S; David M; Dubois J; Powell J; McCuaig CC; Théorêt Y; Kleiber N
    Pediatr Dermatol; 2018 Jul; 35(4):472-477. PubMed ID: 29790593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical Tacrolimus 0.1% for treatment of cutaneous microcystic lymphatic malformations.
    Salvia SA; Amore MA; Papendieck CM
    Lymphology; 2021; 54(2):106-111. PubMed ID: 34735755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA).
    Ozeki M; Asada R; Saito AM; Hashimoto H; Fujimura T; Kuroda T; Ueno S; Watanabe S; Nosaka S; Miyasaka M; Umezawa A; Matsuoka K; Maekawa T; Yamada Y; Fujino A; Hirakawa S; Furukawa T; Tajiri T; Kinoshita Y; Souzaki R; Fukao T
    Regen Ther; 2019 Jun; 10():84-91. PubMed ID: 30705924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of topical rapamycin in the treatment of superficial lymphatic malformations.
    García-Montero P; Del Boz J; Baselga-Torres E; Azaña-Defez JM; Alcaraz-Vera M; Tercedor-Sánchez J; Noguera-Morel L; Vera-Casaño Á
    J Am Acad Dermatol; 2019 Feb; 80(2):508-515. PubMed ID: 30296533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review.
    Wiegand S; Wichmann G; Dietz A
    Lymphat Res Biol; 2018 Aug; 16(4):330-339. PubMed ID: 29924669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series.
    Dodds M; Tollefson M; Castelo-Soccio L; Garzon MC; Hogeling M; Hook K; Boull C; Maguiness S
    Pediatr Dermatol; 2020 Mar; 37(2):272-277. PubMed ID: 31957126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sirolimus in children with lymphatic malformations of the head and neck.
    Wiegand S; Dietz A; Wichmann G
    Eur Arch Otorhinolaryngol; 2022 Aug; 279(8):3801-3810. PubMed ID: 35526176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus in the Treatment of Microcystic Lymphatic Malformations: A Systematic Review.
    Teng JMC; Hammill A; Martini J; Treat J
    Lymphat Res Biol; 2023 Apr; 21(2):101-110. PubMed ID: 35852876
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
    Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
    JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
    Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
    Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus.
    Durand R; Reid JR; Belasco JB; Shellikeri S; Calle-Toro JS; Cahill AM; Srinivasan A
    AJR Am J Roentgenol; 2021 Sep; 217(3):741-752. PubMed ID: 33405944
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical rapamycin and microcystic lymphatic malformations.
    Gu Y; Sebaratnam DF
    J Am Acad Dermatol; 2024 Jan; 90(1):e29-e30. PubMed ID: 37717734
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease.
    Ricci KW; Hammill AM; Mobberley-Schuman P; Nelson SC; Blatt J; Bender JLG; McCuaig CC; Synakiewicz A; Frieden IJ; Adams DM
    Pediatr Blood Cancer; 2019 May; 66(5):e27614. PubMed ID: 30672136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Sirolimus for Treatment of Orbital Lymphatic Malformations: A Systematic Review.
    Shoji MK; Shishido S; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2020; 36(3):215-221. PubMed ID: 31990892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.